Jasmeet Singh

3.9k total citations · 3 hit papers
40 papers, 1.1k citations indexed

About

Jasmeet Singh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jasmeet Singh has authored 40 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jasmeet Singh's work include HER2/EGFR in Cancer Research (24 papers), Cancer Treatment and Pharmacology (13 papers) and Advanced Breast Cancer Therapies (12 papers). Jasmeet Singh is often cited by papers focused on HER2/EGFR in Cancer Research (24 papers), Cancer Treatment and Pharmacology (13 papers) and Advanced Breast Cancer Therapies (12 papers). Jasmeet Singh collaborates with scholars based in United States, Japan and Spain. Jasmeet Singh's co-authors include Hiroji Iwata, Komal Jhaveri, Francisco J. Esteva, Shunji Takahashi, Haeseong Park, Shanu Modi, Corina Taitt, Charles A. Powell, Ian E. Krop and Junji Tsurutani and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Jasmeet Singh

37 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

2020 248 citations Junji Tsurutani, Hiroji Iwata et al. Cancer Discovery profile →
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

2023 124 citations Eric Van Cutsem, Maria Di Bartolomeo et al. The Lancet Oncology profile →
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

2022 121 citations Charles A. Powell, Shanu Modi et al. profile →

Peers

Countries citing papers authored by Jasmeet Singh

Since Specialization

Citations

This map shows the geographic impact of Jasmeet Singh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jasmeet Singh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jasmeet Singh more than expected).

Fields of papers citing papers by Jasmeet Singh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jasmeet Singh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jasmeet Singh. The network helps show where Jasmeet Singh may publish in the future.

Co-authorship network of co-authors of Jasmeet Singh

This figure shows the co-authorship network connecting the top 25 collaborators of Jasmeet Singh. A scholar is included among the top collaborators of Jasmeet Singh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jasmeet Singh. Jasmeet Singh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial 2025 ·Journal of Clinical Oncology ·Charles M. Rudin, Melissa L. Johnson, Luis Paz‐Ares, Makoto Nishio, Christine L. Hann, Nicolas Girard, Pedro Rocha, Hidetoshi Hayashi, Tetsuya Sakai, Yu Jung Kim, Haichuan Hu, Meng Qian, Jasmeet Singh, (unknown), Mei Tang, Myung‐Ju Ahn	0
2	Use of Real‐World Evidence in a Virtual Bridging Analysis for a Human Epidermal Growth Factor Receptor 2–Targeted Antibody–Drug Conjugate in Gastric Cancer 2023 ·The Journal of Clinical Pharmacology ·(unknown), (unknown), Maribel Salas, Jasmeet Singh, Yoshinori Kawaguchi, Andrew J. Belli, Malaz Abutarif, Τushar Garimella	1
3	Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study breakdown → 2023 ·The Lancet Oncology ·Eric Van Cutsem, Maria Di Bartolomeo, Elizabeth Smyth, Ian Chau, Haeseong Park, Salvatore Siena, Sara Lonardi, Zev A. Wainberg, Jaffer A. Ajani, Joseph Chao, Yelena Y. Janjigian, Amy Qin, Jasmeet Singh, Ferdous M. Barlaskar, Yoshinori Kawaguchi, Geoffrey Y. Ku	124
4	Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01) 2023 ·Annals of Oncology ·Cristina Saura, Shanu Modi, Ian E. Krop, Y.H. Park, S.-B. Kim, Kenji Tamura, Hitoshi Iwata, Junji Tsurutani, Joohyuk Sohn, E. Mathias, (unknown), Jillian Cathcart, Jasmeet Singh, Toshinari Yamashita	50
5	P2.16-06 A Phase 2 Study of Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Previously Treated ES-SCLC 2023 ·Journal of Thoracic Oncology ·Charles M. Rudin, Melissa L. Johnson, Nicolas Girard, Christine L. Hann, Myung‐Ju Ahn, Makoto Nishio, (unknown), Marcello Arca, Meng Qian, Jasmeet Singh, L. Paz-Ares	1
6	1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen 2022 ·Annals of Oncology ·Geoffrey Y. Ku, Maria Di Bartolomeo, (unknown), Ian Chau, (unknown), Salvatore Siena, Sara Lonardi, (unknown), Jaffer A. Ajani, Joseph Chao, (unknown), Yoshiaki Kawaguchi, A. Qin, Jasmeet Singh, Gudrun Meinhardt, E. Van Cutsem	21
7	Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study 2022 ·Breast Cancer ·Carol Mansfield, (unknown), (unknown), Kathleen Klein, Kongming Wang, Jasmeet Singh, Michelle D. Hackshaw	3
8	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab 2022 ·npj Breast Cancer ·Emanuela Ferraro, Jasmeet Singh, Sujata Patil, Pedram Razavi, Shanu Modi, Sarat Chandarlapaty, Andrea V. Barrio, Rachna Malani, Ingo K. Mellinghoff, Adrienne Boire, Hannah Y. Wen, Edi Brogi, Andrew D. Seidman, Larry Norton, Mark E. Robson, Chau T. Dang	13
9	Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review 2022 ·Breast Cancer Research and Treatment ·Edith A. Perez, Chau T. Dang, Caleb Lee, Jasmeet Singh, Kongming Wang, J. Bradley Layton, Alicia Gilsenan, Michelle D. Hackshaw, Javier Cortés	16
10	279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01) 2021 ·Annals of Oncology ·C. Saura Manich, Shanu Modi, Ian E. Krop, Y.H. Park, S-B. Kim, Kenji Tamura, Fabrice André, Hiroji Iwata, (unknown), Junji Tsurutani, Joohyuk Sohn, (unknown), (unknown), Jillian Cathcart, Jasmeet Singh, Toshinari Yamashita	22
11	Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients 2021 ·Drugs & Aging ·Jasmeet Singh, Stuart M. Lichtman	2
12	LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen 2021 ·Annals of Oncology ·Eric Van Cutsem, Maria Di Bartolomeo, (unknown), Ian Chau, (unknown), Salvatore Siena, Sara Lonardi, Zev A. Wainberg, Jaffer A. Ajani, Joseph Chao, (unknown), Yoshiaki Kawaguchi, A. Qin, Jasmeet Singh, Gudrun Meinhardt, Geoffrey Y. Ku	23
13	Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer 2020 ·Breast Cancer Research and Treatment ·Michelle D. Hackshaw, Heather E. Danysh, Jasmeet Singh, Mary E. Ritchey, (unknown), Corina Taitt, D. Ross Camidge, Hiroji Iwata, Charles A. Powell	66
14	289P Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies 2020 ·Annals of Oncology ·Charles A. Powell, D. Ross Camidge, Shanu Modi, A. Qin, Corina Taitt, (unknown), Michelle D. Hackshaw, Jasmeet Singh, Hiroji Iwata	18
15	Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors breakdown → 2020 ·Cancer Discovery ·Junji Tsurutani, Hiroji Iwata, Ian E. Krop, Pasi A. Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles H. Redfern, Kenji Tamura, Trisha M. Wise‐Draper, Kaku Saito, Masahiro Sugihara, Jasmeet Singh, Takahiro Jikoh, Gilles Gallant, Bob T. Li	248
16	340P Patient preferences for HER2-targeted treatment of advanced or metastatic breast cancer in the United States 2020 ·Annals of Oncology ·Carol Mansfield, (unknown), (unknown), Kathleen Klein, (unknown), Jasmeet Singh, (unknown)	1
17	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer 2019 ·JAMA Network Open ·Neil M. Iyengar, Lillian M. Smyth, Diana Lake, Ayca Gucalp, Jasmeet Singh, Tiffany A. Traina, Patricia DeFusco, Monica Fornier, Shari Goldfarb, Komal Jhaveri, Shanu Modi, Tiffany A. Troso-Sandoval, Sujata Patil, Gary A. Ulaner, Maxine S. Jochelson, Larry Norton, Clifford A. Hudis, Chau T. Dang	6
18	Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study 2016 ·Breast Cancer Research and Treatment ·Lillian M. Smyth, Neil M. Iyengar, (unknown), (unknown), Sujata Patil, (unknown), (unknown), Jasmeet Singh, Sarat Chandarlapaty, S. Sugarman, Elizabeth Comen, Pamela Drullinsky, Tiffany A. Traina, Tiffany A. Troso-Sandoval, José Baselga, Larry Norton, Clifford A. Hudis, Chau T. Dang	20
19	Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients 2015 ·Drugs & Aging ·Jasmeet Singh, Stuart M. Lichtman	6
20	HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development 2014 ·British Journal of Cancer ·Jasmeet Singh, Komal Jhaveri, Francisco J. Esteva	87

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact